No Data
Kanghua Biological (300841.SZ): has repurchased 2.64% of the shares.
On September 2nd, Kanghua Biotech (300841.SZ) announced that as of August 31, 2024, the company has repurchased a total of 3,558,675 shares of its own stock through a dedicated stock buyback account using the centralized auction trading method. This represents 2.64% of the company's current total share capital. The highest fill price was 63.26 yuan/share, and the lowest fill price was 45.97 yuan/share. The total transaction amount was 188,052,434.19 yuan (excluding transaction costs). The buyback complies with the company's buyback plan and relevant laws and regulations.
Individual Investors Are Chengdu Kanghua Biological Products Co., Ltd.'s (SZSE:300841) Biggest Owners and Were Hit After Market Cap Dropped CN¥399m
Chengdu Kanghua Biological Products achieved double-digit growth in revenue and net income in the first half of the year, and implemented an employee stock ownership plan to build a value community.
After achieving double growth in revenue and net income attributable to shareholders in 2023, Chengdu Kanghua Biological Products once again reported good performance in the first half of this year. On the evening of August 16th, Chengdu Kanghua Biological released its half-year performance. The financial report showed that in the first half of this year, Chengdu Kanghua Biological achieved a revenue of 0.741 billion yuan, an increase of 16.81% year-on-year. The net income attributable to shareholders of the listed company was 0.307 billion yuan, an increase of 23.51% year-on-year. At the same time, the company's non-recurring net profit and net cash flows from operating activities also improved significantly. In addition to stable sales of the core product - Recombinant Human Papillomavirus (Type 16,18) Bivalent Vaccine,
Chengdu Kanghua Biological Products: Half-year report for the year 2024.
Chengdu Kanghua Biological Products: Summary of Half-Year Report in 2024.
Chengdu Kanghua Biological Products (300841.SZ) plans to launch an employee stock ownership plan in 2024.
Chengdu Kanghua Biological Products (300841.SZ) disclosed its employee stock ownership plan (draft) for 2024. The stock ownership plan is intended to use the ...
Is Weakness In Chengdu Kanghua Biological Products Co., Ltd. (SZSE:300841) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?No Data
No Data
